3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
84
Breast Neoplasms
10
Neoplasm Metastasis
7
Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
4
Prostate Cancer Metastatic
4
Metastatic Castration-Resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
3
Castration-resistant Prostate Cancer
3
Triple Negative Breast Neoplasms
2
Castration Resistant Metastatic Prostate Cancer
2
Adenocarcinoma of the Prostate
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Primary Breast Cancer ER+ve
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoadjuvant Therapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Interventions
Pemetrexed
3
Gemcitabine
3
Topotecan
2
Carboplatin
2
vosaroxin
1
vinflunine
1
taxane
1
pembrolizumab
1
lurtotecan
1
liposomal doxorubicin
1
enzalutamide
1
bemiparin
1
apalutamide
1
abiraterone
1
Vinorelbine
1
Temozolomide
1
RRx-001
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Ipilimumab
1
Etoposide
1
Docetaxel
1
Cisplatin
1
BI 2536
1
Arsenic Trioxide
1
ARQ 197
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Small Cell
×
enzalutamide
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts